Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

Amycretin mimics the actions of glucagon-like peptide-1 (GLP-1) and amylin, hormones that play a role in reducing blood sugar ...

Amycretin, an oral weight loss drug, led to up to 13% body weight reduction in three months, showing potential for continued ...

However, after its phase 1 success with TERN-601, it will raise more money by taking advantage of its soaring stock price and ...

A new weight loss pill called amycretin has helped people lose up to 13% of their body weight in just three months, according ...

Another contender has emerged in the race to develop oral GLP-1 drugs for weight loss. Biolexis Therapeutics’ small molecule ...

People taking the experimental drug amycretin were found to lose almost twice as much weight over a 12-week period as the ...

The compound was oral amycretin -- an amylin and GLP-1 receptor co-agonist -- said Agnes Gasiorek, PhD, MSc Pharm, of Novo Nordisk in Måløv, Denmark. It's the first long-acting compound to target both ...

An experimental weight-loss pill helped people drop 13% of their body weight in a three-month period. The results from early ...

The maker of injectable weight loss drugs including Ozempic and Wegovy is touting the results of an early-stage trial that ...

Amycretin, a dual pathway, oral weight loss drug, was found to be safe and tolerable in a phase 1 study and led to weight loss of up to 13% in people with overweight and obesity.